ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Daniel P. O'Hair
Robert P. McManus
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Hair, D. P.
Right arrow Articles by Komorowski, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Hair, D. P.
Right arrow Articles by Komorowski, R.

Ann Thorac Surg 1994;58:1311-1315
© 1994 The Society of Thoracic Surgeons

Articles

Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil

Daniel P. O'Hair, MD*, Robert P. McManus, MD, Richard Komorowski, MD

Departments of Cardiothoracic Surgery and Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin USA

* Address reprint requests to Dr O'Hair, Department of Cardiothoracic Surgery, Columbia Presbyterian Medical Center, 177 Fort Washington Ave, Milstein Hospital Building 7-435, New York, NY 10032.

Similar to human allografts, cardiac xenografts also appear susceptible to chronic vascular rejection. The study described here evaluated the influence of mycophenolate mofetil on the incidence and severity of vascular rejection in a primate model of heart xenotransplantation. Nine baboons received heterotopic cardiac xenografts from donor cynomolgus monkeys. All baboons were placed on a cyclosporine and methylprednisolone-based immunosuppressive regimen. In addition, group 1 baboons received azathioprine (4 mg · kg–1 · day–1) and group 2 baboons received mycophenolate mofetil (70 mg · kg–1 · day–1). Biopsy specimens were obtained at regular intervals and reviewed blindly by a pathologist. A total of 50 biopsy specimens, 29 from group 1 and 21 from group 2, were reviewed. Histologic evidence of vascular rejection was present in 16 of the 29 biopsy specimens from the group 1 animals and in only 2 of the 21 specimens from the group 2 animals (p < 0.005). The mean graft survival was 3 months in group 1 versus 10 months in group 2. At 1-year follow-up, profound intimal proliferation in the coronary vasculature was noted in the biopsy specimens from group 1, whereas the coronary vessels were found to be normal in the specimens from group 2. The use of mycophenolate mofetil, in combination with cyclosporine and steroids, resulted in reduced vascular rejection and prolonged xenograft survival.




This article has been cited by other articles:


Home page
 LupusHome page
G R V Hughes and H Phillips
Mycophenolate mofetil and cardiovascular disease
Lupus, November 1, 2006; 15(11_suppl): 1 - 2.
[Abstract] [PDF]

Home page
 LupusHome page
R D Mamelok
Effects of mycophenolate mofetil on transplant coronary artery disease and survival following cardiac transplantation
Lupus, November 1, 2006; 15(11_suppl): 18 - 22.
[Abstract] [PDF]

Home page
 LupusHome page
W T Gibson and M R Hayden
Mycophenolate mofetil and animal models
Lupus, November 1, 2006; 15(11_suppl): 27 - 34.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
E. Ilkay, L. Tirikli, I. Ozercan, M. Yavuzkir, I. Karaca, A. Rahman, and N. Arslan
Oral Mycophenolate Mofetil Prevents In-Stent Intimal Hyperplasia Without Edge Effect
Angiology, October 1, 2006; 57(5): 577 - 584.
[Abstract] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. Badid, A. Desmouliere, and M. Laville
Mycophenolate mofetil: implications for the treatment of glomerular disease
Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1752 - 1756.
[Full Text] [PDF]

Home page
 QJMHome page
A.N. Warrens
The evolving role of mycophenolate mofetil in renal transplantation
QJM, January 1, 2000; 93(1): 15 - 20.
[Full Text] [PDF]

Home page
 FASEB J.Home page
C. COSTA, L. ZHAO, W. V. BURTON, K. R. BONDIOLI, B. L. WILLIAMS, T. A. HOAGLAND, P. A. DITULLIO, K. M. EBERT, and W. L. FODOR
Expression of the human {alpha}1,2-fucosyltransferase in transgenic pigs modifies the cell surface carbohydrate phenotype and confers resistance to human serum-mediated cytolysis
FASEB J, October 1, 1999; 13(13): 1762 - 1773.
[Abstract] [Full Text]

Home page
 Ann. Thorac. Surg.Home page
R. I. Whyte, S. J. Rossi, M. S. Mulligan, R. Florn, L. Baker, S. Gupta, F. J. Martinez, and J. P. Lynch III
Mycophenolate Mofetil for Obliterative Bronchiolitis Syndrome After Lung Transplantation
Ann. Thorac. Surg., October 1, 1997; 64(4): 945 - 948.
[Abstract] [Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. E. Michler, A. S. Shah, S. Itescu, D. P. O'Hair, S. Tugulea, P. A. Kwiatkowski, Z. Liu, J. L. Platt, E. A. Rose, and N. Suciu-Foca
THE INFLUENCE OF CONCORDANT XENOGRAFTS ON THE HUMORAL AND CELL-MEDIATED IMMUNE RESPONSES TO SUBSEQUENT ALLOGRAFTS IN PRIMATES
J. Thorac. Cardiovasc. Surg., October 1, 1996; 112(4): 1002 - 1009.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1994 by The Society of Thoracic Surgeons.